NeuroOne Medical Technologies Corporation has elevated Emily Johns to the expanded role of Chief Administrative Officer and General Counsel, a move that strengthens the company's operational infrastructure during a critical growth phase. Johns, who joined NeuroOne earlier this year as General Counsel, will now oversee human resources, compliance, security, and risk management in addition to continuing to lead the company's legal strategy.
This executive promotion comes as NeuroOne develops and commercializes minimally invasive solutions for EEG recording, stimulation, and ablation treatments for patients suffering from epilepsy, Parkinson's disease, dystonia, essential tremors, and chronic pain due to failed back surgeries. The company's technologies aim to improve patient outcomes while reducing procedural costs, with potential future applications in depression, mood disorders, pain management, incontinence, high blood pressure, and artificial intelligence.
Dave Rosa, President and CEO of NeuroOne, emphasized the significance of Johns' expanded role, stating that she has already made impactful contributions to the organization and future business growth. The promotion reflects the company's commitment to strengthening operations as it scales to bring what it describes as life-changing technologies to more patients worldwide.
Johns brings substantial experience to her expanded responsibilities, having most recently served as a partner at Honigman LLP, where she represented numerous life sciences companies, including NeuroOne on all transactional work since 2017. Her background includes beginning her career at Sullivan & Cromwell LLP, where she represented public companies in securities offerings and mergers and acquisitions transactions.
The leadership expansion is particularly important given the complex regulatory environment surrounding medical technology development and the increasing demand for innovative neurological treatments. As NeuroOne continues to advance its technologies through clinical trials and commercialization efforts, strong administrative oversight becomes increasingly critical for navigating regulatory requirements, managing organizational growth, and maintaining compliance with Nasdaq listing standards.
For investors and stakeholders following the company's progress, this executive promotion signals NeuroOne's focus on building robust operational infrastructure to support its ambitious growth plans. The company's forward-looking statements indicate ongoing commitment to scaling operations and infrastructure to expand access to its technologies, though these statements are subject to various risks and uncertainties outlined in SEC filings available through https://www.sec.gov.
NeuroOne's corporate information and ongoing developments can be monitored through its investor relations resources at https://www.nmtc1.com, where the company provides updates on its progress in developing solutions for neurological disorders that affect millions of patients globally.
